BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36328877)

  • 21. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
    Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
    Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma.
    Kobayashi Y; Miura K; Hojo A; Hatta Y; Tanaka T; Kurita D; Iriyama N; Kobayashi S; Takeuchi J
    J Cancer Res Clin Oncol; 2011 Jul; 137(7):1079-84. PubMed ID: 21221637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China.
    Bai JF; Han HX; Feng R; Li JT; Wang T; Zhang CL; Liu H
    Oncologist; 2020 Aug; 25(8):e1202-e1208. PubMed ID: 32436258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy and Safety of THP-COP for Diffuse Large B-Cell Lymphoma].
    Watase M; Takahashi K; Hanazawa N; Shinohara Y; Higashi T; Tsukada J
    Gan To Kagaku Ryoho; 2017 Jan; 44(1):53-57. PubMed ID: 28174380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
    Purdum A; Tieu R; Reddy SR; Broder MS
    Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The efficacy and adverse effects of rituximab with CHOP or THP-COP in old-old and extremely old patients with diffuse large B cell lymphoma].
    Kikukawa M; Miyazaki K; Kiuchi A; Abe S; Fujii H; Kanaya K; Shin K; Iwamoto T
    Nihon Ronen Igakkai Zasshi; 2006 Mar; 43(2):236-40. PubMed ID: 16683659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients.
    Długosz-Danecka M; Szmit S; Ogórka T; Skotnicki AB; Jurczak W
    Cancer Med; 2019 Mar; 8(3):1103-1109. PubMed ID: 30740919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
    Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z
    Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
    McMillan AK; Phillips EH; Kirkwood AA; Barrans S; Burton C; Rule S; Patmore R; Pettengell R; Ardeshna KM; Lawrie A; Montoto S; Paneesha S; Clifton-Hadley L; Linch DC
    Ann Oncol; 2020 Sep; 31(9):1251-1259. PubMed ID: 32464282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
    Savage KJ; Al-Rajhi N; Voss N; Paltiel C; Klasa R; Gascoyne RD; Connors JM
    Ann Oncol; 2006 Jan; 17(1):123-30. PubMed ID: 16236753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma.
    Hirakawa T; Yamaguchi H; Yokose N; Gomi S; Inokuchi K; Dan K
    Ann Hematol; 2010 Sep; 89(9):897-904. PubMed ID: 20414658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry.
    Kida S; Fuji S; Morishima T; Nakata K; Miyashiro I; Ishikawa J
    Int J Hematol; 2021 Aug; 114(2):246-251. PubMed ID: 33864237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study.
    Juul MB; Jensen PH; Engberg H; Wehberg S; Dessau-Arp A; Haziri D; Kristensen HB; Baech J; Schurmann L; Clausen MR; Valentin R; Knudsen LM; Munksgaard L; El-Galaly TC; Frederiksen H; Larsen TS
    Eur J Cancer; 2018 Aug; 99():86-96. PubMed ID: 29935491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H; Fan L; Fu D; Lin Q; Shen J
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
    J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 39. Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP.
    Hara T; Tsurumi H; Goto N; Kanemura N; Yoshikawa T; Kasahara S; Yamada T; Sawada M; Goto H; Fukuno K; Kitagawa J; Yasuda I; Katsumura N; Takemura M; Takahashi T; Takami T; Moriwaki H
    J Cancer Res Clin Oncol; 2009 Oct; 135(10):1421-8. PubMed ID: 19381687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
    Wieringa A; Boslooper K; Hoogendoorn M; Joosten P; Beerden T; Storm H; Kibbelaar RE; Veldhuis GJ; van Kamp H; van Rees B; Kluin-Nelemans HC; Veeger NJ; van Roon EN
    Br J Haematol; 2014 May; 165(4):489-96. PubMed ID: 24754632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.